Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand

Alexandria, VA (PRWEB) May 30, 2015

On Thursday, May 14, the Mesothelioma Applied Research Foundation interviewed Dr. Charles Simone and Dr. Evan Alley both of the University of Pennsylvania Medicine, during its 'Meet the Mesothelioma Experts' series. The interview was part of the series of interviews focusing on mesothelioma centers of excellence. Drs. Simone and Alley were interviewed by the Meso Foundation's executive director, Mary Hesdorffer, with whom they discussed the mesothelioma program at the University of Pennsylvania Medicine.

The full interview is now available on demand on the Meso Foundation's website at http://www.curemeso.org/experts.

Drs. Alley and Simone are the co-directors of the Penn Mesothelioma and Pleural Program.

Dr. Alley is a medical oncologist and is the leading investigator in the PD-1 inhibitor trial that has recently made big news in mesothelioma. Read more about the trial here.

Dr. Simone treats patients with malignant pleural mesothelioma with photon and proton radiation therapy and photodynamic therapy (PDT). He is a National Institutes of Health and Department of Defense funded investigator who performs clinical and translational research investigating the novel use of proton therapy and PDT as definitive therapy and as part of multi-modality therapy for mesothelioma.

You can listen to previous Meet the Mesothelioma Experts sessions on our Meet the Mesothelioma Experts page.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. An estimated one-third of those who develop mesothelioma were exposed while serving in the Navy or working in shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $9 million to research. More information is available at http://www.curemeso.org.

###

Read the full story at http://www.prweb.com/releases/2015/05/prweb12755598.htm

You May Also Be Interested In

• InvestorNewsBreaks – Diamond Lake Minerals Inc. (DLMI), BOXABL Announce Partnership to Bring Affordable Housing to the Public, Digital Tokens to Investors
• IFR Closes Over Subscribed Brokered Offering of Units
• AUTODESK, INC. (NASDAQ: ADSK) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Autodesk, Inc.